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Abstract: Mastocytosis is a rare hematological neoplasm characterized by the proliferation of 
abnormal clonal mast cells (MCs) in different cutaneous and extracutaneous organs. Its diagnosis is 
based on well-defined major and minor criteria, including the pathognomonic dense infiltrate of 
MCs detected in bone marrow (BM), elevated serum tryptase level, abnormal MCs CD25 expression, 
and the identification of KITD816V mutation. The World Health Organization (WHO) classification 
subdivides mastocytosis into a cutaneous form (CM) and five systemic variants (SM), namely 
indolent/smoldering (ISM/SSM) and advanced SM (AdvSM) including aggressive SM (ASM), SM 
associated to hematological neoplasms (SM-AHN), and mast cell leukemia (MCL). More than 80% 
of patients with SM carry a somatic point mutation of KIT at codon 816, which may be targeted by 
kinase inhibitors. The presence of additional somatic mutations detected by next generation 
sequencing analysis may impact prognosis and drive treatment strategy, which ranges from 
symptomatic drugs in indolent forms to kinase-inhibitors active on KIT. Allogeneic stem cell 
transplant (SCT) may be considered in selected SM cases. Here, we review the clinical, diagnostic, 
and therapeutic issues of SM, with special emphasis on the translational implications of SM genetics 
for a precision medicine approach in clinical practice. 
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1. Introduction 
Mastocytosis is a rare hematological neoplasm characterized by heterogenous 
clinical manifestations due to the excessive proliferation of abnormal clonal mast cells 
(MCs) in different cutaneous and extracutaneous sites, such as bone marrow (BM), spleen, 
lymph nodes, and the gastrointestinal (GI) tract [1]. Mastocytosis has historically been a 
diagnostic challenge due to the constellation of presenting symptoms, thus resulting in 
underestimation of disease incidence and prevalence. The estimated prevalence of 
systemic mastocytosis (SM) is 1/10,000 adults, and the estimated incidence amounts to 
1/100,000 per year [2].  
The clinical presentation of mastocytosis is very heterogeneous and ranges from 
skin-limited disease in cutaneous mastocytosis (CM), as typically observed in pediatric 
cases with a spontaneous regression in puberty, to diffuse extracutaneous involvement 
with more aggressive presentations in adult patients, named systemic mastocytosis (SM) 
with multiorgan dysfunction and shorter survival [3–5]. The clinical approach to SM 
requires multidisciplinary collaboration of hematologists, gastroenterologists, 
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dermatologists, specialists of bone diseases, and allergogists [6]. The increased knowledge 
in SM genetics and the wider availability of molecular diagnostic tests have resulted in an 
improvement in the recognition and treatment of this rare disease. Approximately 90% of 
mastocytosis is associated with somatic gain-of-function point mutations in KIT [7]. 
However, the presence of additional somatic mutation in different genes, such as SRSF2, 
ASXL1, RUNX1, EZH2, and loss of function of SETD2, may impact the disease course, 
especially in the aggressive forms of SM, and may drive a personalized therapeutic 
approach [8–10]. Indeed, adult SM is managed with a tailored approach ranging from 
symptomatic treatment aimed at reducing the release of the MCs mediators and 
controlling their effects in indolent SM to target cytoreductive therapy in the aggressive 
variants of SM.  
Historically, SM has been treated with interferon-α (INF-alfa), cladribine, and 
imatinib in selected cases; however, the advent of kinase inhibitors targeting the KIT 
receptor offered encouraging perspectives [11,12]. Allogeneic stem cell transplantation 
(SCT) may be an option in selected SM associated with hematological neoplasms (SM-
AHN) [13,14]. Due to heterogeneous presentation and the unpredictable behavior of the 
different variants of SM, correct classification and accurate risk assessments are 
mandatory in order to offer the best treatment options to SM patients. Here, we review 
the clinical, diagnostic, and therapeutic issues of SM, underlining how the recent impact 
of molecular biology may guide the approach of clinicians. 
2. Clinical Presentation and Diagnostic Work-Up 
According to the 2016 revision of World Health Organization (WHO) classification 
of myeloid neoplasm, mastocytosis is considered a distinct entity within 
myeloproliferative neoplasms (Table 1) [1]. Clinical presentation is widely heterogenous, 
and the multisystemic involvement may require a multidisciplinary diagnostic approach. 
Clinicians should conduct comprehensive evaluations of signs and symptoms with 
special consideration of triggers of MCs activation and a complete medical history, 
including the presence of repeated anaphylactic episodes after Hymenoptera sting. 
Unexplained osteoporosis, especially in men, as well as unexplained lymphadenopathy 
and/or splenomegaly, may trigger the suspicion of mastocytosis. 
Table 1. WHO 2016 classification of mastocytosis. 
Cutaneous Mastocytosis (CM) 
• Macupapular CM 
• Diffuse CM 
• Mastocytoma of skin 
Systemic mastocytosis (SM) 
• Indolent systemic mastocytosis (ISM) * 
• Smoldering systemic mastocytosis (SSM) * 
• Systemic mastocytosis with an associated hematological neoplasm (SM-AHN) 
• Aggressive systemic mastocytosis (ASM) * 
• Mast cell leukemia (MCL) 
Mast cell sarcoma (MCS) 
* Requires additional information regarding B and C finding for accurate diagnosis [15,16]. See 
Table 3 for details *. 
Laboratory tests may evidence eosinophilia, elevated acid uric and lactate 
dehydrogenase (LDH), alteration in liver function tests (LFTs), and increased serum 
tryptase level, which is an important indicator of MCs activation. A key point of 
mastocytosis diagnosis is represented by the bone marrow aspirate and bone marrow 
biopsy or biopsy of extracutaneous involved organ. Flow cytometry and 
immunohistochemistry are both mandatory for diagnosis [17]. On the contrary, molecular 
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testing on peripheral blood (PB) or BM to detect KIT D816V or other less frequent KIT 
mutations, as detailed below, by conventional polymerase chain reaction (PCR) or allele-
specific oligonucleotide quantitative PCR (ASO-qPCR) especially in low MC burden plays 
a crucial role in diagnostic work-up and also has therapeutic implications [18,19]. FISH is 
required in SM-AHN cases. NGS analysis with a myeloid mutation panel, as detailed 
below, may increase the information in terms of survival [18,20]. A proposed diagnostic 
framework for mastocytosis is proposed in Figure 1. 
 
Figure 1. Diagnostic workup of a patient with suspected mastocytosis. The diagnostic workup of a 
patient with suspected mastocytosis should start with personal medication history, physical 
examination, counseling about triggers that may increase MCs activation, and collection of signs 
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and symptoms. A multidisciplinary approach is useful. Laboratory tests include CBC with manual 
differential, serum tryptase level, BM biopsy with IHC for detection of CD25, and flow cytometry 
for MCs CD25 and in selected cases of CD30 expression if IHC is not available [21]. Molecular testing 
for KITD816V mutation (in BM, PB, or other lesions) should be performed, as well as for FIP1L1-
PDGFRA if eosinophilia is present. If available, the NGS test may be assessed. Major and minor 
criteria should be reached. After the identification of SM, B and C findings should be defined for the 
correct identification of SM variants. Abbreviations: MCs, mast cells; CBC, complete blood count; 
BM, bone marrow; IHC, immunohistochemistry; PB, peripheral blood; SM, systemic mastocytosis; 
NGS, next generation sequencing; MIS, mastocytosis in the skin; SM-AHN, systemic mastocytosis 
associated with a hematological neoplasm; ISM, indolent systemic mastocytosis; SSM, smoldering 
systemic mastocytosis; ASM, aggressive systemic mastocytosis; MCL, mast cell leukemia. 
The WHO has proposed well-defined major and minor criteria for diagnosis (Table 
2) [1]. The diagnosis of SM is established when major criteria and at least one of the minor 
criteria, or at least three minor criteria, are present. BM is almost always involved in adult 
mastocytosis, showing clusters of abnormal MCs for morphology (fusiform, with polar 
cytoplasmic process and cytoplasmatic hypo-granularity) and phenotypes (abnormal 
MCs usually express CD25). In addition, BM examination may allow the identification of 
an associated hematologic neoplasm (Figure 2) [22–25]. The abnormal MCs usually ex-
press CD25, which is considered a more representative marker than CD2 [17,26]. Elevated 
levels of serum tryptase are virtually detected in all SM cases but are not specific for mas-
tocytosis, since they may also increase in different myeloid neoplasms, namely acute my-
eloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndromes 
(MDS). When the diagnostic criteria for SM are met, SM is then subclassified by the iden-
tification of additional “B” and “C” findings summarized in Table 3. Based on the afore-
mentioned clinical, histological, immunophenotypic, and biological aspects, SM is classi-
fied into five variants: indolent systemic mastocytosis (ISM), smoldering systemic masto-
cytosis (SSM), systemic mastocytosis with an adjunctive hematological neoplasm (SM-
AHN), aggressive systemic mastocytosis (ASM), and mast cell leukemia (MCL) [27]. ASM, 
SM-AHN, and MCL have been defined as “advanced SM” (AdvSM) due to their worse 
prognosis compared to the other subtypes [5,27]. A precise identification of the SM sub-
type is a relevant goal of the diagnostic framework of mastocytosis due to its implications 
for the therapeutic approach. 
 
Figure 2. Bone marrow histology of patient affected by SM. Panel A: Giemsa; 40×: perivascular spin-
dle-shaped mast cells with abnormal cytologic features (spindling and hypogranularity). Panel B: 
CD117; 40×: in tissue sections, an immunohistochemical stain can be used for identification of 
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mastcells. Panel C: immunostaining with CD25 shows an atypical immunophenotype of mast cells 
with membrane reactivity. 
Table 2. Diagnostic Criteria for Systemic Mastocytosis (SM) according to the 2016 WHO classifica-
tion. 
Major criterion 
Multifocal, dense infiltrate of atypical MCs (≥15 MCs in 
aggregates) in BM biopsy and/or in section of other 
extracutaneous organs  
Minor criteria 
a. >25% of atypical or spindle shaped MCs in BM sections 
or other extracutaneous organs 
b. KIT point mutation at codon 816 in BM or PB or other 
extracutaneous organs 
c. MCs in BM or PB or other extracutaneous organs 
exhibit CD25 with or without CD2, in flow cytometry and 
immunochemistry, if available.  
d. Baseline serum tryptase value >20 ng/mL  
Abbreviations: WHO, World Health Organization; SM, systemic mastocytosis; MCs, mast cells; 
BM, bone marrow; PB, peripheral blood. 
Table 3. Definition of B and C findings for Systemic Mastocytosis (SM). 
B—Findings 
• Hight MCs infiltration in BM: ≥30% in histology and basal serum tryptase level > 
200 ng/mL  
• BM with sign of dysplasia or myeloproliferation, without substantial cytopenia 
and without criteria of an associated hematological neoplasm and without sub  
• Organomegaly without impaired organ function: hepatomegaly, palpable 
splenomegaly, and/or palpable lymphadenopathy (or on CT or US) 
C—Findings 
• BM dysfunction: ≥1 cytopenia (ANC < 1. 109/L, Hbg < 10 g/dL, platelet < 100 × 
109/L) 
• Hepatomegaly and liver disfunction with ascites  
• Palpable splenomegaly with hypersplenism  
• Skeletal involvement with large size osteolysis with or without pathological 
fractures * 
• Malabsorption with hypoalbuminemia and weight loss  
• Live threatening organ damage in other organ systems due to local MCs 
infiltration 
Abbreviations: MCs, mast cells; BM, bone marrow; CT, computerized tomography; US, ultra-
sound; ANC, absolute neutrophil count. * Pathological fractures caused by osteoporosis are not C-
findings. 
Indolent and Smoldering Systemic Mastocytosis. ISM is the most common variant of 
SM and is characterized by a slowly progressive clinical course with life expectancy com-
parable to the general population. The diagnosis of ISM meets the criteria of SM in the 
absence of the “B or C finding”. ISM has relatively good prognosis in terms of overall 
survival (OS) and leukemia-free survival (LFS) compared with ASM and SM-AHN [5,28]. 
SSM is a new SM category in the WHO classification, previously mentioned as a provi-
sional subvariant of ISM. Compared to ISM, SSM was associated with older age, as ex-
pected from disease definition, with higher bone marrow MC burden, higher serum tryp-
tase level, and higher prevalence of palpable hepatomegaly and splenomegaly. SSM is 
currently considered an intermediate variant and is characterized by the presence of ≥ 2 
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“B findings”, thus, a high burden of MCs [29]. SSM prognosis is better than AdvSM but 
worse than ISM [29–31].  
Aggressive Mastocytosis. Aggressive SM is characterized by the presence of “C find-
ings”. Patients may display constitutional symptoms, hepatosplenomegaly, lymphade-
nopathies, severe anemia and/or thrombocytopenia, leukocytosis, and very high serum 
tryptase levels. Due to the massive release of mediators by MCs, clinical manifestations 
may be present in different organs and systems, including the (GI) tract with abdominal 
pain, diarrhea, nausea vomiting, peptic ulcer, and GI bleeding [32–34]. Depression, mus-
culoskeletal pain, and osteopenia with or without osteoporosis may also occur [34,35]. In 
a series of 342 SM patients, the OS of ASM was 41 months [5]. 
Systemic Mastocytosis with an Associated Hematological Neoplasm (SM-AHN). SM-
AHN displays a more aggressive clinical course versus the other aforementioned variants 
and it is frequently observed in older patients [5]. Hematological malignancies mostly as-
sociated with SM include chronic myelomonocytic leukemia (CMML), MDS, myeloprolif-
erative neoplasms (MPN), AML, B-cell lymphoma, and plasma cell neoplasms [36]. 
Among 342 consecutive patents with SM, 123 had an SM-AHN subdivided in SM-MPN 
(45%), SM-CMML (29%), SM-MDS (23%), and SM-AL (3%) [37]. After a median follow-up 
of 15 months, 90 (73%) deaths were recorded (100% with SM-AL, 89% SM-CMML, 82% 
SM-MDS, and 56% with SM-MPN). SM-MPN cases had significantly longer median sur-
vival (31 months) compared with SM-CMML, SM-MDS, and SM-AL [37]. Leukemic trans-
formation is higher in SM-MDS than in SM-CMML [37]. 
Mast Cell Leukemia. MCL is a rare and extremely aggressive variant of SM and is 
characterized by the highest mortality. It is also considered a form of acute leukemia, de-
fined by the presence of at least 20% neoplastic MCs in the BM and 10% in the PB. The 
spread of MCs may affect different organs with typical aggressive manifestations, such as 
constitutional symptoms, cytopenia, hepatic malfunction, hypersplenism, and malabsorp-
tion [38,39]. In addition to driver mutation KIT D816V, somatic mutations in SRF2, ASXL1, 
RUNX1, TET2, CBL, K/N-RAS, and EZH2 have been identified in MCL patients, explain-
ing, at least in part, the more aggressive course and poorer survival of MCL compared to 
other SM variant [40].  
3. Molecular Aspects: KIT and beyond as Biomarkers of the Disease 
MCs originate from hematopoietic progenitor cells in the BM and, after a partial dif-
ferentiation, are released as precursors in the bloodstream; reach tissues and organs; and 
complete their maturation, differentiation, and proliferation [41]. These processes and the 
survival of MCs are strongly dependent upon the binding of stem cell factor (SFC) to the 
extracellular domain of the KIT receptor [42,43].  
The KIT proto-oncogene is located on the long arm of chromosome 4 (4q11-4q13) and 
contains 21 exons (Figure 3). KIT encodes a type III tyrosine-kinase (TK) receptor, which 
is detailed in Figure 3 [42,44]. In SM, KIT mutations result in the constitutive activation of 
the receptor, resulting in MCs proliferation, differentiation, survival, migration, and cyto-
kine production. Indeed, more than 90% typical ISM and 70% of AdvSM carry an acquired 
point mutation in the KIT gene. The most common activating loop mutation of KIT is 
D816V, replacing aspartic acid with valine at codon 816 and resulting in its constitutive 
activation [45]. Occasionally, other variants targeting the same codon, such as D816Y, 
D816F, D816H, and D816I, have been described [46]. 




Figure 3. KIT structure and related activation pathway in mastocytosis. The proto-oncogene KIT encodes a type III tyro-
sine-kinase (TK) receptor, consisting of an extracellular domain (ECD) with five immunoglobulin-like motives, that in-
cludes the stem cell factor (SCF) binding site, a transmembrane domain (TMD), a juxta membrane domain (JMD), and two 
catalytic tyrosine kinase domains with ATP and phosphotransferase domain (PTD) binding site, separated by a kinase 
insert [42,44]. In normal conditions, the SCF ties the KIT binding site leading to receptor dimerization, autophosphoryla-
tion and kinase domain activation. Consequentially, it triggers a cascade of multimolecular phosphorylation resulting in 
different signal transduction pathways, such as the Janus kinase (JAK) and the signal transducers and activators of tran-
scription (STAT), the phosphatidylinositol triphosphate kinase (PI3K), the rat sarcoma (RAS), and extracellular signal-
regulated kinase (ERK) pathway [42,47–49]. In SM, KIT is constitutively activated, resulting in MCs proliferation, differ-
entiation, survival, migration, and cytokine production. 
The advent of NGS allowed the deep molecular characterization of SM patients be-
yond the sole KIT mutation. Additional somatic mutations (e.g., TET2, SRSF2, ASXL1, 
EZH2, CBL, RUNX1, and RAS) have been found in 90% of AdvSM patients, especially in 
SM-AHN [50–52]. In a series of 70 patients affected by AdvSM, the most frequently mu-
tated genes identified by NGS were TET2 (47%), SRSF2 (43%), ASXL1 (29%), RUNX1 
(23%), JAK2V617F (16%), N/KRAS (14%), CBL (13%), and EZH2 (10%). Less frequently mu-
tated genes were IDH2, ETV6, U2AF1, SF3B1, MLL, NPM1, DNMT3A, and TP53. Sixty 
percent of patients harbor two or more mutations, in addition to KITD816V. Mutations in 
SRSF2 and ASXL1 are independent predictors that adversely influence OS. A worse OS 
associates with the number of concurrent mutations in SRSF2/ASXL1/RUNX1 (S/A/R) that 
have been incorporated in the mutation adjusted risk score (MARS) system for SM [52]. A 
similar panel of mutated genes has been described by Pardanani et al. in a study of 150 
cases of SM and myeloid diseases. The most frequently mutated genes were TET2 (29%), 
ASXL1 (17%), and CBL (11%), with a significantly higher mutation frequency in SM-AHN. 
ASXL1 and RUNX1 mutations were associated with inferior survival in AdvSM [53]. 
Based on the impact of mutations on OS, molecular information in addition to KIT D816V 
identification has been incorporated into prognostication risk assessment. 
Recently, great attention has been given to the SETD2 gene due to its implication in 
cancer. The human SETD2 gene is located at cytogenetic band p21.31 of chromosome 3, a 
region frequently targeted by copy number loss in various tumors [54]. The SETD2 protein 
consists of 2564 amino acids and has a molecular weight of 287.5 KD. SETD2 is responsible 
for tri-methylation of lysine 36 on histone H3 (H3K36me3) that is correlated with tran-
scriptional activation and also contributes to DNA double-strand break repair in response 
to DNA damage [55,56]. Martinelli et al. reported loss of function mutations of SETD2 in 
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a series of 53 SM patients and have suggested that reduced SETD2 expression/absence 
and H3K36Me3 deficiency might potentiate the effects of KIT constitutive activation to 
determine the phenotype of advanced SM [54].  
4. Cytogenetic Information 
Cytogenetic analyses are performed at diagnosis in a minority of patients with 
AdvSM, and few data are available. Previous data reported similar cytogenetic abnormal-
ities in SM and in MPN, such as trisomy 8, trisomy 9, and del(20)(q11), suggesting com-
mon pathogenetic pathways in MSc and myeloid disorders [57]. In a study of 34 patients 
with either urticaria pigmentosa or systemic mastocytosis, chromosome abnormalities 
were found in 41% of the patients in at least one examination [58]. In a retrospective study 
of 109 patients with ISM and AdvSM with or without AHN, an aberrant karyotype was 
identified in 22% of cases [59]. According to their aberrant karyotype, the patients were 
stratified in two different cytogenetic groups. Normal karyotypes and favorable karyo-
types such as del(5q), trisomy 8, del(1q), and del(12p) were classified in the good risk 
group, while complex karyotypes defined as ≥3 abnormalities and monosomy 7 were clas-
sified in the poor-risk group (n = 10). The median OS of poor-risk karyotype patients was 
significantly shorter than good-risk/normal karyotype patients, and the karyotype was 
confirmed as an independent prognostic variable in AdvSM [51,52]. In another large ret-
rospective study of the Mayo Clinic on 348 consecutive SM, the karyotype was abnormal 
in 15% cases, including 6% of ISM, 26% of SM-AHN, 8% of ASM, and 28% of SM-AHN-
myeloid (p < 0.001). No significant associations between abnormal karyotype and presence 
of adverse mutations have been demonstrated [60]. In univariate analysis, abnormal kar-
yotype was associated with inferior survival in ASM and SM-AHN, but this finding was 
not confirmed in multivariate analysis. In this study, patients were also screened for the 
most common somatic mutations of myeloid disease, and the mutation status was prog-
nostically more relevant than karyotype. In conclusion, no SM-specific cytogenetic aber-
rations have been identified, and information about the incidence and impact of cytoge-
netic aberrations in terms of survival is limited. 
5. Risk Stratification 
The five subgroups of SM identified by the WHO 2016 classification carry relevant 
differences in disease presentation and natural history of disease [1]. However, in addition 
to the WHO subtype, advanced age, history of weight loss, anemia, thrombocytopenia, 
hypoalbuminemia, and presence of BM blasts > 5% impact survival [5]. The advent of NGS 
has allowed greater accuracy in terms of prognostic stratification. Different studies have 
suggested different prognostic score systems combining clinical and molecular variables, 
summarized in Table 4. Pardanani et al. sequenced 27 genes in 150 SM patients and iden-
tified different mutations and variables that integrated into a clinical-molecular prognos-
tic model allowing deep prognostication of AdvSM patients [53]. Based on these grounds, 
the Mayo Clinic group proposed the Mutation-Augmented Prognostic Scoring System 
(MAPSS), stratifying AdvSM into three distinct risk groups: low-risk (score 0–1.5), inter-
mediate-risk (score 2–4.5), and high-risk (score 5–7.5) with median survival of 5, 21, and 
86 months, respectively [61]. Jawhar et al. performed the MARS system for patients with 
AdvSM that integrates clinical and mutation characteristics. The study included 383 pa-
tients with AdvSM from the German Registry on Disorders of Eosinophils and Mast Cells 
as training set and a series from the European Competence Network on Mastocytosis as 
the validation set [62]. In multivariable analysis, age > 60 years, hemoglobin less than 10 
g/dL, thrombocytopenia (platelets < 100 × 109/L), presence of one high molecular risk gene 
mutation (i.e., SRSF2, ASXL1, and/or RUNX1) (S/A/R), and presence of two or more high 
molecular risk gene mutations were associated with shorter OS. The presence and number 
of gene mutations in the S/A/R panel had a strong adverse impact on OS. Three risk cate-
gories were defined: low risk (median OS, not reached), intermediate risk (median OS, 3.9 
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years), and high risk (median OS, 1.9 years). The MARS system was independent of the 
WHO classification type and was confirmed in the independent validation set [63].  
Table 4. Different prognostic score risk stratifications for Systemic Mastocytosis (SM). 
MARS [64] MAPS [63] IPSS for No AdvSM [65] IPSS for AdvSM 
Prognostic variable and points 
Age > 60 years 1 Age > 60 years 1 Age > 60 years 1 Age > 60 years 1 
Hemoglobin < 10 g/dL 1 
Advanced SM vs. 
ISM/SSM 2 ALP ≥ 100 U/L 1 
Tryptase ≥ 125 
ng/mL 1 
Platelets < 100 × 109/L 1 Platelets < 150 × 109/L 1   
Leukocytes ≥ 16 × 
109/L 1 
One S/A/R (SFRS2, 
ASXL, or RUNX1) 
mutation 
1 Serum ALP > normal range 1   
Hemoglobin ≤ 11 
g/dL 1 
≥2 S/A/R mutation 2 
Adverse mutation 
(ASXL1, RUNX1 and 
NRAS) 
1   Platelets <150 × 109/L 1 
      Skin involvement −1 
Risk group and points 
Low 0–1 Low ≤2 Low 0 AdvSM-1 −1 to 0 
Intermediate 2 Intermediate- 1 3 Intermediate-1 1 AdvSM-2 1 
High 3–5 Intermediate-2 4 Intermediate-2 2 AdvSM-3 2 
  High ≥5   AdvSM-4 2–3 
      AdvSM-5 4–5 
Abbreviations: MARS, Mutation-Adjusted Risk Score for advanced systemic mastocytosis; MAPS, Mayo Alliance Prog-
nostic System for mastocytosis; IPSS, International Prognostic Scoring System for non-advanced systemic mastocytosis; 
S/A/R, presence of SRSF2 and/or ASXL1 and/or RUNX1 mutation; SRFS2, Serine And Arginine Rich Splicing Factor 2; 
ASXL1, Additional Sex Combs-Like Transcriptional Regulator 1; RUNX1, Runt-related transcription factor 1 SM, systemic 
mastocytosis; ISM, indolent systemic mastocytosis; SSM, smoldering systemic mastocytosis; ALP, alkaline phosphatase; 
NRAS, NRAS proto-oncogene; AdvSM, advanced systemic mastocytosis. 
Subsequently, the Mayo Alliance Prognostic System (MAPS) was developed; the clin-
ical, cytogenetic, and molecular information of 580 patients, referred to Mayo Clinic from 
1968 to 2015, was analyzed [63]. Two complementary risk models were elaborated: a clin-
ical and a hybrid clinical-molecular model. The clinical model confirmed the independent 
prognostic contribution of five variables: WHO defined AdvSM type, platelets <150 × 
109/L, increased ALP, age more than 60 years, and anemia. The hybrid clinical-molecular 
model replaced anemia with adverse mutations (i.e., ASXL1, RUNX1, and NRAS) as a risk 
factor [63]. Recently, an international study of the registry of the European Competence 
Network on Mastocytosis developed the International Prognostic Scoring System of Mas-
tocytosis (IPSM) in a series of 1639 patients with SM [65]. IPSM divided patients with non-
AdvSM into three groups based on age >60 years and elevated ALP value: low (no risk 
factors), intermediate 1 (one risk factor), and intermediate 2 (two risk factors). In patients 
with AdvSM, age 60 years or older, a concentration of tryptase ≥125 ng/mL, a leukocyte 
count ≥16 × 109/L, hemoglobin ≤11 g/dL or a platelet count ≤100 × 109/L, and skin involve-
ment were prognostic variables. Four risk categories were established for AdvSM with 
significantly different outcomes for OS and progression-free survival. IPSM was con-
firmed using a validation cohort from the Spanish network Red Española de Mastocitosis. 
IPSM is now commonly used to predict survival outcomes and to guide treatment deci-
sions. 
  




Treatment of mastocytosis aims to control the symptoms of MCs activation and 
degranulation in indolent forms and to decrease MCs infiltration and reduce organ dam-
age in the advanced forms. Major advances have occurred in the last 5 years regarding 
treatment of SM including new TKIs targeting KIT. Cytoreductive and immunomodulant 
drugs, such as cladribine or interferon, may be other options for disease control, and head-
to-head comparisons with targeted therapies are lacking. A critical issue is whether the 
patient is eligible for allogeneic SCT and what might be the appropriate timing for trans-
plant. Figure 4 summarizes the current available treatment options for SM. 
Inhibition of MC activation and degranulation. Symptoms of SM can be managed by 
blocking the mediator receptors (H1 and H2 antihistamines; leukotriene receptor block-
ade), inhibiting mediator synthesis (aspirin and zileuton) or release (sodium cromolyn), 
by anti-IgE therapy, or by a combination of these approaches [66]. Combinations of base-
line anti-H1 no-sedating medicines (e.g., cetirizine or levocetirizine) with the addition of 
sedating medications for breakthrough symptoms or at bedtime (such as diphenhydra-
mine or hydroxyzine) and an H2 blocker are recommended [66]. H2 and proton pump 
inhibitors, such as ranitidine, cimetidine, or famotidine, can also address GI symptoms 
[66]. 
Patients with SM often suffer from MCs’ activation syndrome, which is mediated by 
clonal MCs, but in most cases the syndrome is also IgE-dependent with a high-risk of 
developing severe anaphylactic reactions [67]. Acute episodes of MCs activation require 
epinephrine, whereas prolonged episodes may be addressed with corticosteroids. Omali-
zumab, an IgE depleting drug, appears to prevent some life-threatening reactions associ-
ated with mastocytosis and may be a good option for treating the associated symptoms, 
although its use is supported only by observational and uncontrolled studies including 
small numbers of patients [68,69]. Neuropsychiatric symptoms associated with the pres-
ence of elevated MCs mediators, including anxiety or depression, may benefit of antide-
pressants and anxiolytic medications [70]. Purely symptomatic treatment may not suffice 
in some patients who require a reduction in MCs burden in order to prevent severe symp-
toms including anaphylaxis and/or progression to aggressive diseases. 
Sarilumab. A phase 2 study to evaluate the safety and efficacy of Sarilumab in im-
proving the quality of life in ISM is ongoing (NCT03770273). Sarilumab is approved by 
the Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis [71]. 
The binding of sarilumab to the IL-6 receptor inhibits IL-6-associated human mast cell 
signaling and proliferation with decreased mediator release. Based on these grounds, sari-
lumab may be a rational choice for the treatment of ISM. 
Siglec-8 targeting (AK002). In bone marrow aspirates from patients with SM, all acti-
vated mast cells display a robust expression of the Siglec-8 receptor [72]. A novel human-
ized monoclonal antibody to Siglec-8 (AK002) demonstrated SM mast cell inhibition in ex 
vivo bone marrow aspirates. AK002 also had depleting effects on eosinophils, which may 
be valuable to SM patients with associated eosinophilia. These encouraging results may 
represent a novel approach for the treatment of SM [72]. 
KIT inhibitors. The main advances in SM treatment are related to the inhibition of 
KIT D816V, which is the primary driver of MCs differentiation, proliferation, and survival 
in the overwhelming majority of patients. 
Imatinib. KIT D816V is resistant to imatinib due to a conformational change in the 
enzymatic pocket that blocks the binding of the drug to the receptor, and nilotinib and 
dasatinib also lack significant clinical activity [73,74]. However, imatinib inhibits the 
growth of MCs with wild-type KIT or with mutations outside the KIT activation loop that 
target the extracellular (e.g., deletion of codon 419 on exon 8 or p.A502_Y503dup in exon 
9), transmembrane (e.g., F522C), or juxtamembrane (e.g., V560G) domains. These muta-
tions occur in <1% of all AdvSM cases and are enriched in cases of well-differentiated SM 
[75]. Imatinib has been approved by the Food and Drug Administration for SM patients 
negative for KITD816V or with unknown KIT mutation status. A recent clinical trial and 
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a systematic review carried out by the Red Española de Mastocitosis clarified that predic-
tors of imatinib response in SM are the presence of imatinib-sensitive mutations involving 
KIT (e.g., juxtamembrane or transmembrane KIT mutations). Conversely, the sole absence 
of KITD816V does not per se represent a positive predictor of imatinib response [76]. 
 
Figure 4. Proposal treatment algorithm for systemic mastocytosis. Proposal treatment algorithm for 
systemic mastocytosis. SM-AHN, systemic mastocytosis associated a hematological neoplasm; ISM, 
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indolent systemic mastocytosis; SSM, smoldering systemic mastocytosis; ASM, aggressive systemic 
mastocytosis; MCL, mast cell leukemia; HSCT, hematopoietic stem cell transplant; * Enroll patients 
in clinical trial, if available. 
Midostaurin. Midostaurin is an inhibitor of PKC that can also target several clinically 
relevant kinases, including KIT, FLT3, PDGFRA, PDGFRB, vascular endothelial growth 
factor receptor KDR, and FES, both in their wild type and mutated forms [77]. In vitro, 
midostaurin was proven not only to induce apoptosis and growth arrest in KIT mutated 
cell lines and in neoplastic MCs from patients with AdvSM but also to suppress IgE-re-
ceptor mediated activation and mediator release in human MCs and blood basophils 
[78,79]. In a phase II trial of midostaurin in AdvSM on 89 patients with ASM, SM-AHN, 
or MCL, the overall response rate (ORR) was 60%, the median OS was 28.7 months, and 
the progression-free survival was 14.1 months [11]. Importantly, a decrease in mastocyto-
sis related symptoms was observed in responding patients. At the dosage of 100 mg twice 
daily in 4-week cycles, the most common side-effects were low-grade nausea, vomiting, 
and diarrhea, whereas severe cytopenia occurred in <50% of patients. Of note, most pa-
tients were already cytopenic before treatment [11]. In another phase II trial on 26 patients 
with AdvSM and organ damage treated with the same midostaurin schedule, the median 
OS was 40 months (18.5 months for MCL patients) and the ORR was 69% at the median 
follow-up of 10 years, with clinical benefit in all AdvSM variants [12]. A single case report 
and a small patients series confirmed these results [80,81]. In patients with slow progres-
sion, treatment with midostaurin can induce major clinical responses with improvement 
or disappearance of C-findings, a decrease in MC burden in the BM and other organs, and 
a reduction in mediator-related symptoms in a significative number of patients, with 
moderate gastroenteric side effects [11,12,82–87]. Midostaurin may be used both as first-
line treatment, especially in MCL patients, as well as salvage therapy in patients progress-
ing after interferon-α, cladribine, or other cytoreductive therapy. Other possible roles for 
midostaurin include maintenance therapy after allogeneic SCT or for control of severe 
MCs activation symptoms [18]. 
Avapritinib (BLU-285). Avapritinib is an oral potent and selective tyrosine kinase in-
hibitor of PDGFRA and of the activation-loop mutants of KIT, including KITD816V [88]. 
It is highly selective with limited inhibitory activity outside of KIT and PDGFRA kinases 
and has shown therapeutic activity in murine models of mastocytosis. A phase 1 trial (Ex-
plorer; NCT02561988) enrolled 52 AdvSM. Rapid antineoplastic activity was assessed by 
BM MCs burden, serum tryptase, and KIT D816V mutant allele burden. Among the 52 
enrolled patients, only twenty-three were evaluable for response by IWG-MRT-ECNM 
criteria [89]. The ORR and the rate of CR plus CR with partial recovery of peripheral blood 
counts (CR/CRh) were 83% and 17%, respectively. Responses were obtained also in pa-
tients who experienced intolerance or no response relative to prior midostaurin. Adverse 
effects (AEs) were myelosuppression with thrombocytopenia and anemia, periorbital and 
peripheral edema, fatigue, nausea, vomiting, diarrhea, and cognitive effects. Treatment 
discontinuation occurred because of progession, AEs or inadequate response in 33%, 33%, 
and 17%, respectively. The protocol was modified to manage severe thrombocytopenia 
with strict dose interruption or reduction. Follow up of the phase 2 study (Pathfinder; 
NCT03580655) is ongoing. More data are needed to assess long-term responses and ad-
verse effects of this novel TKI. 
Ripretinib (DCC-2618). DCC-2618 is a new Type II switch pocket control inhibitor 
that has shown a potent inhibitory effect on exon 17 KIT mutations and that is resistant to 
other TKI [90]. The safety and tolerability of DCC-2618 in patients with advanced malig-
nancies, including SM, is under study (NCT02571036). At the time of writing, the drug is 
approved for GastroIntestinal Stromal Tumors (GIST) by the FDA and European Medi-
cines Agency (EMA).  
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Masitinib. In a phase 3 study, 135 patients with ISM or SSM were randomly assigned 
masitinib (n = 71) or a placebo (n = 64). By 24 weeks, masitinib was associated with a cu-
mulative response of 18.7% in the primary endpoint (≥75% improvement from baseline 
within weeks 8–24 in at least one severe baseline symptom) compared with 7.4% for the 
placebo (p = 0.0076). Frequent severe adverse events included diarrhea (11% vs. 2% in the 
masitinib group vs. the placebo group), rash (6% vs. none), and asthenia (6% vs. 2%). The 
most frequent serious adverse events included diarrhea (4%) and urticaria (3%), and no 
life-threatening toxicities occurred. These findings indicate that masitinib may be an ef-
fective and well tolerated agent for the treatment of severely symptomatic ISM or SSM 
[91]. A phase 3 study comparing oral masitinib to placebo for the treatment of SSM or 
ISSM, unresponsive to optimal symptomatic treatment, is ongoing (NCT04333108). 
BLU-263 (KIT inhibitor). BLU-263 is an investigational, potent, and selective oral 
small-molecule inhibitor of KIT with sub-nanomolar potency on D816V-mutant KIT. A 
randomized, double-blind, and placebo-controlled phase 2/3 study comparing the efficacy 
and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with 
ISM whose symptoms are not adequately controlled by BSC is currently recruiting 
(NCT04910685). 
Bezuclastinib (PLX9486) PLX9486 has selective activity against primary KIT muta-
tions (exons 9 and 11) and activation loop mutations (exons 17 and 18). Based on the re-
sults of PLX9486 in GIST, a recent interest has focused on the use of this drug on SM [92]. 
A phase 2 open-label multicenter clinical study of the safety, efficacy, pharmacokinetic, 
and pharmacodynamic profiles of CGT9486 (formally named PLX9486) as a single agent 
in patients with AdSM is ongoing (NCT04996875). 
6.1. BLC-2 Inhibitors 
Obatoclax. Recent data suggest that MCs in AdvSM express several antiapoptotic 
members of the Bcl-2 family, including Bcl-2, and myeloid leukemia cell differentiation 
protein 1 (Mcl-1) [93,94]. Obatoclax (GX015-070) is a novel BH3 mimetic small molecule 
type targeted drug that binds to and blocks the antiapoptotic activity of Mcl-1 and Bcl-2 
[95] [35–37]. Based on its activity in preclinical models, obatoclax has been recently inves-
tigated by Peter at al., showing that obatoclax may be an effective drug capable of sup-
pressing the growth and survival in neoplastic MC in advanced SM [96]. Further studies 
are required to define its potential value and in vivo efficacy in advanced SM. 
Cladribine. In two large series of SM patients treated with cladribine as single agent, 
the ORRs were 50% to 82% in patients with AdvSM and 60% to 92% in patients with ISM, 
with significant improvement in multiple symptoms [82,83]. In the study with the longer 
follow-up (>10 years), the median duration of response was 3.71 and 2.47 years for indo-
lent and aggressive M, respectively, with immunosuppression and opportunistic infec-
tions as main toxicities and the latter occurring as grade 3 or 4 in a minority of patients 
(13%) [82]. Cladribine is active in all SM subtypes, with response rates similar to those 
reported with midostaurin, although there is no direct comparison, and the analysis is 
limited by small patient numbers. Cladribine may be used as first-line treatment when 
rapid disease debulking is needed or as salvage treatment in patients failing treatments 
[18].  
Interferon-α. As reported since 1992, the administration of interferon alpha-2b has 
potential benefits in the treatment of mastocytosis [97]. INF-α and INF-α2b can reduce 
MCs degranulation and BM infiltration by MCs, can improve the typical cutaneous and 
GI signs, and can increase bone density [98–100]. INF-α is effective on all types of SM; 
however, the ORR is approximately around 20%, and no fixed dose and duration have 
been firmly established. Side effects, including cytopenia, liver toxicity and elevated trans-
aminases, fatigue, nausea, fever, flu-like syndrome, and psychiatric sequelae, occur fre-
quently, resulting in treatment discontinuation. To ameliorate tolerability and reduce dis-
continuation due to the side effects, INF-α has been administered in combination with 
prednisone [101]. In a series of 47 SM patients, INF-α with or without prednisone was 
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administered. The dosage of INF-α ranged from 0.5 million units (MU) per day to 10 MU 
three times a week, and prednisone ranged from 20 mg to 60 mg per day. The ORR of the 
40 evaluable cases was 53%, while CR, major response (MR), and PR were obtained in 3%, 
15%, and 35% of cases, respectively [83]. The overall median duration of response was 12 
months, and the responses were not significantly different between the arms with or with-
out prednisone.  
Allogenic stem cell transplant. In a large cooperative study on 57 patients with SM 
who underwent allogeneic SCT, 40 patients (70%) achieved a response at day + 100. Sex-
teen patients (28%) achieved CR, including 2 patients who became KITD816V-negative 
[13]. All 38 SM-AHN patients achieved a response, whereas half of the MCL patients were 
primary refractory. OS at 3 years was 57% for all patients, 74% in AHN group, 43% in 
AdvSM, and 17% in MCL group. Survival was lower in patients receiving reduced inten-
sity conditioning compared with myeloablative conditioning and in patients in progres-
sion [13]. Allogeneic SCT can be considered in patients with associated hematological dis-
ease such as AML or in those with relapsed/refractory AdvSM [14,18]. In the event of a 
possible transplantation, a careful evaluation of the induction regiment is mandatory, pre-
ferring cladribine or small molecules to IFN based treatment due the increased risk of 
acute graft versus host disease (aGVHD) [14]. 
6.2. Future Perspectives 
Despite many advances in the molecular genetics and precision medicine approach 
of SM, several issues deserve to be explored further with respect to this disease. From a 
therapeutic standpoint, CD123 is the α-subunit of the interleukin-3 receptor (ILR3) and 
represents a potential attractive therapeutic target in systemic mastocytosis (SM) given its 
absent expression on normal/reactive mast cells (MCs) and aberrant expression on neo-
plastic MCs. A recent study has suggested that targeting CD123 in SM may have direct 
and indirect anti-tumor effects [99]. A phase I study is currently investigating the best 
dose and side effects of the anti-CD123 flotetuzumab monoclonal antibody for the treat-
ment of patients with CD123-positive relapsed or refractory hematological disease, in-
cluding SM patients (NCT04681105) [100]. Tagraxofusp (SL-401) is a CD123-directed cy-
totoxin consisting of human interleukin-3 fused to truncated diphtheria toxin. It has been 
investigated in the blastic plasmacytoid dendritic-cell neoplasm (BPDCN), showing 
promising results [101], and deserves to be explored also in SM. Given a certain degree of 
heterogeneity in CD123 expression in SM, clinical trials based on anti-CD123-targeted 
therapy should be coupled with investigations aimed at correlating expression levels and 
outcome. As detailed above, the advances in understanding of biology and treatment of 
SM have been limited by the rarity of the disease and by the relative low number of MCs 
infiltrating the patients’ tissues. To overcome this limitation, Toledo et al. generated the 
induced pluripotent stem cells (iPSCs) from patients with aggressive SM, which repre-
sents a new approach for disease modeling and screening for precision medicine. Using 
these iPSCs, the authors identified nintedanib, which is a FDA approved angiokinase in-
hibitor that targets the vascular endothelial growth factor receptor (EGFR) and fibroblast 
growth factor receptor, as a novel KIT D816V inhibitor [102,103]. Table 5 summarizes the 
main recruiting clinical trials in SM. 
Table 5. Principal recruiting clinical trials involving SM. 
Clinicaltrials.Go
v Identifier Intervention Title Primary Outcome Measures 
NCT03770273 Sarilimus 
A Phase 2 Randomized Double-
Blinded Placebo-Controlled Study 
to Evaluate the Safety and Efficacy 
of Subcutaneous Sarilumab in 
Improving the Quality of Life in 
Frequency and severity of adverse events 
(AEs); mastocytosis Quality of Life 
Questionnaire (MC-QoL) 
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Subjects with Indolent Systemic 
Mastocytosis 
NCT04333108 Masitinib 
Phase 3 Study to Compare Oral 
Masitinib to Placebo in Treatment 
of Patients with Smouldering or 
Indolent Severe Systemic 
Mastocytosis, Unresponsive to 
Optimal Symptomatic Treatment 
Cumulative response in at least one of three 
severe baseline symptoms of mast cell 
mediator release (pruritus, flushes, or 
depression).  
NCT04910685 BLU-263 
A Randomized, Double-Blind, 
Placebo-Controlled Phase 2/3 
Study of BLU-263 in Indolent 
Systemic Mastocytosis  
Recommended Dose (RD) in patients with 
ISM; response rate in patients with ISM; 
long-term safety and tolerability of BLU-
263 as assessed by the number of adverse 
events and serious adverse events; mean 
change in Indolent Systemic Mastocytosis, 
Symptom Assessment Form (ISM-SAF) 




A 3-Part, Randomized, Double-
Blind, Placebo-Controlled Phase 2 
Study to Evaluate Safety and 
Efficacy of Avapritinib (BLU-285), 
a Selective KIT Mutation-Targeted 
Tyrosine Kinase Inhibitor, in 
Indolent and Smoldering Systemic 
Mastocytosis With Symptoms 
Inadequately Controlled With 
Standard Therapy 
Recommended Phase 2 dose (RP2D) in 
patients with ISM; proportion of 
responders, defined as ≥30% reduction in 





A Phase 2 Open-Label, 
Multicenter Clinical Study of the 
Safety, Efficacy, Pharmacokinetic, 
and Pharmacodynamic Profiles of 
CGT9486 as a Single Agent in 
Patients With Advanced Systemic 
Mastocytosis 
Determine the optimal dose of CGT9486 by 
safety assessments and response criteria; 
objective response rate according to 




Specific Killer Engager (TriKE™) 
for the Treatment of HighRisk 
Myelodysplastic Syndromes, 
Refractory/Relapsed Acute 
Myeloid Leukemia and Advanced 
Systemic Mastocytosis 
Maximum Tolerated Dose (MTD) of GTB-
3550 TriKE™ finding; incidence of 
complete and partial remission due to GTB-
3550 TriKE™ treatment 
NCT04681105 Flotetuzumab 
A Phase 1 Trial to Evaluate the 
Safety of Single Agent 
Flotetuzumab in Advanced 
CD123-Positive Hematological 
Malignancies 
Maximum tolerated dose (recommended 
phase 2 dose, RP2D) of flotetuzumab; 
evaluate the safety and tolerability of 
flotetuzumab in CD123-positive advanced 
ALL) (Cohort A) and other hematological 
malignancies (Cohort B), by evaluation of 
toxicities including: type, frequency, 
severity, attribution, and duration of the 
toxicity. 
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The current scenario of rapidly changing paradigm for hematological malignancies 
mandates a systematic collection of patient-reported outcomes (PRO) and quality of life 
(QoL) data in both clinical research and in routine care [104]. Quality of life (QoL) and 
patient reported outcomes (PROs) have been explored to a limited extent in SM and de-
serve to be investigated in detail given the high burden of symptoms of many of these 
patients. A recent report has documented a high level of suffering and strong associations 
between impairments and symptom-related factors in the disease, pointing to the need of 
further addressing this issue [105]. Similarly to other myeloid malignancies, the use of 
disease adapted scoring systems for QoL and PROs may result in a better understanding 
of the patient’s perspective of symptoms and result in an improvement of disease man-
agement also in SM [106–108]. 
7. Conclusions 
The diagnosis of SM might be challenging, and a multidisciplinary approach is de-
sirable due to a broad variety of signs and symptoms driven by MCs degranulation. The 
disease pathogenesis is clearly driven by KIT mutations; however, new molecular tech-
nologies have allowed highlighting new genetic features that are involved in disease path-
ogenesis and may contribute to refining diagnostication and prognostication. In particu-
lar, the use of NGS has allowed building different prognostic scores, which may guide 
clinicians in terms of patient stratification and treatment choice. Resistance to the first 
generation TKI imatinib has resulted in exploring the potential utility of new selective 
TKIs, such as midostaurin and avapritinib, which have demonstrated activity against SM 
harboring the KITD816V mutation. Encouraging results of anti-CD123 antibodies in he-
matological malignances may be investigated in MCs disease. Large collaborative efforts 
are needed to clarify the different open questions related to the diagnosis and treatment 
of SM. 
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